Clinical Interest in Exome-Based Analysis of Somatic Mutational Signatures for Non-Small Cell Lung Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Sep 14

PMID 39272973

Authors

Morgane Peroz

Hugo Mananet

Nicolas Roussot

Coureche Guillaume Kaderbhai

Valentin Derangere

Caroline Truntzer

Francois Ghiringhelli

Affiliations

Soon will be listed here.

Abstract

Background: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality. This study investigates the clinical interest of whole exome sequencing (WES) for analyzing somatic mutational signatures in patients with advanced or metastatic NSCLC treated with the current standard of care.

Methods: Exome sequencing data and clinical characteristics from 132 patients with advanced or metastatic NSCLC were analyzed. Somatic mutational signatures including single base substitutions (SBSs), double base substitutions (DBSs), and copy number signatures were evaluated. Structural variations including tumor mutational burden (TMB), the number of neoantigens, TCR clonality, homologous recombination deficiency (HRD), copy number alterations (CNAs), and microsatellite instability (MSI) score were determined. The association between these genomic features, NSCLC subtypes, and patient outcomes (progression-free and overall survival) was evaluated.

Conclusions: Exome sequencing offers valuable insights into somatic mutational signatures in NSCLC. This study identified specific signatures associated with a poor response to immune checkpoint inhibitor (ICI) therapy and chemotherapy, potentially aiding treatment selection and identifying patients unlikely to benefit from these approaches.

References

Schuster-Bockler B, Lehner B . Chromatin organization is a major influence on regional mutation rates in human cancer cells. Nature. 2012; 488(7412):504-7. DOI: 10.1038/nature11273. View

Niogret J, Dalens L, Truntzer C, Chevrier S, Favier L, Lagrange A . Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?. Lung Cancer. 2021; 161:98-107. DOI: 10.1016/j.lungcan.2021.08.013. View

Ready N, Hellmann M, Awad M, Otterson G, Gutierrez M, Gainor J . First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. J Clin Oncol. 2019; 37(12):992-1000. PMC: 6494267. DOI: 10.1200/JCO.18.01042. View

Zhao P, Li L, Jiang X, Li Q . Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019; 12(1):54. PMC: 6544911. DOI: 10.1186/s13045-019-0738-1. View

Bolotin D, Poslavsky S, Mitrophanov I, Shugay M, Mamedov I, Putintseva E . MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015; 12(5):380-1. DOI: 10.1038/nmeth.3364. View

Hendriks L, Kerr K, Menis J, Mok T, Nestle U, Passaro A . Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34(4):358-376. DOI: 10.1016/j.annonc.2022.12.013. View

Hendriks L, Kerr K, Menis J, Mok T, Nestle U, Passaro A . Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34(4):339-357. DOI: 10.1016/j.annonc.2022.12.009. View

Diaz-Gay M, Vangara R, Barnes M, Wang X, Islam S, Vermes I . Assigning mutational signatures to individual samples and individual somatic mutations with SigProfilerAssignment. Bioinformatics. 2023; 39(12). PMC: 10746860. DOI: 10.1093/bioinformatics/btad756. View

Holder A, Dedeilia A, Sierra-Davidson K, Cohen S, Liu D, Parikh A . Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer. 2024; 24(7):498-512. DOI: 10.1038/s41568-024-00705-7. View

10.

Saunders C, Wong W, Swamy S, Becq J, Murray L, Cheetham R . Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics. 2012; 28(14):1811-7. DOI: 10.1093/bioinformatics/bts271. View

11.

Owen D, Singh N, Ismaila N, Masters G, Riely G, Robinson A . Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2. J Clin Oncol. 2023; 41(24):e63-e72. DOI: 10.1200/JCO.23.01055. View

12.

Yang H, Ma W, Sun B, Fan L, Xu K, Hall S . Smoking signature is superior to programmed death-ligand 1 expression in predicting pathological response to neoadjuvant immunotherapy in lung cancer patients. Transl Lung Cancer Res. 2021; 10(9):3807-3822. PMC: 8512473. DOI: 10.21037/tlcr-21-734. View

13.

Sztupinszki Z, Diossy M, Krzystanek M, Reiniger L, Csabai I, Favero F . Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer. 2018; 4:16. PMC: 6028448. DOI: 10.1038/s41523-018-0066-6. View

14.

Cibulskis K, Lawrence M, Carter S, Sivachenko A, Jaffe D, Sougnez C . Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-9. PMC: 3833702. DOI: 10.1038/nbt.2514. View

15.

Otlu B, Diaz-Gay M, Vermes I, Bergstrom E, Zhivagui M, Barnes M . Topography of mutational signatures in human cancer. Cell Rep. 2023; 42(8):112930. PMC: 10507738. DOI: 10.1016/j.celrep.2023.112930. View

16.

Ha G, Roth A, Khattra J, Ho J, Yap D, Prentice L . TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. Genome Res. 2014; 24(11):1881-93. PMC: 4216928. DOI: 10.1101/gr.180281.114. View

17.

Alexandrov L, Nik-Zainal S, Wedge D, Campbell P, Stratton M . Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013; 3(1):246-59. PMC: 3588146. DOI: 10.1016/j.celrep.2012.12.008. View

18.

Mosele F, Remon J, Mateo J, Westphalen C, Barlesi F, Lolkema M . Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020; 31(11):1491-1505. DOI: 10.1016/j.annonc.2020.07.014. View

19.

Dalens L, Niogret J, Kaderbhai C, Boidot R . Is There a Role for Large Exome Sequencing in the Management of Metastatic Non-Small Cell Lung Cancer: A Brief Report of Real Life. Front Oncol. 2022; 12:863057. PMC: 8940536. DOI: 10.3389/fonc.2022.863057. View

20.

Jaiyesimi I, Leighl N, Ismaila N, Alluri K, Florez N, Gadgeel S . Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3. J Clin Oncol. 2024; 42(11):e1-e22. DOI: 10.1200/JCO.23.02744. View